Program
tucatinib
Also written as “Tucatinib”, “Tucatinib (ONT-380)” and “ARRY-380, HER2 inhibitor; oral”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Uterine Cervical Neoplasms · Adenocarcinoma Of Esophagus · Neoplasms, led by 4 companies.
Drug pageTucatinib: every studyAll 55 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 218 open or running | phase 4since Aug 12, 2026 | Mar 31, 2008 | Dec 31, 2026phase 1 · NCT05382364 |
| Criteriumits history only | 22 open or running | phase 2since Dec 27, 2021 | Dec 27, 2021 | Jun 1, 2027phase 2 · NCT05458674 |
| AstraZenecaits history only | 11 open or running | phase 2since Aug 31, 2020 | Aug 31, 2020 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Nov 12, 2020 | Nov 12, 2020 | none ahead |
Also a collaborator on its studies: Novartis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2020First study: phase 2 study in Advanced Unresectable or Metastatic Solid MalignancyFirst studyNCT04632992 · 252 enrolled · United States
TargetBeta
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States | 2 | Completed | Dec 4, 2023 | 252 |
How it is read
Names in the registry
- “Tucatinib”, 12 entries
- “tucatinib”, 11 entries
- “Tucatinib (ONT-380)”, 1 entry
- “ARRY-380, HER2 inhibitor; oral”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 11 studies
- Colorectal Neoplasms, 3 studies
- Uterine Cervical Neoplasms, 2 studies
- Adenocarcinoma Of Esophagus, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.